# An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma

> **NCT00207116** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 120 (—)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung
- Neoplasm Metastasis

## Interventions

- **DRUG:** Cetuximab

## Key facts

- **NCT ID:** NCT00207116
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** 2006-03
- **Final completion:** 2006-03
- **Target enrollment:** 120 (—)
- **Last updated:** 2015-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00207116

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00207116, "An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00207116. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*